This effect is reversible with the glycolysis inhibitor 2-deoxy-D-glucose, indicating that the SOX2/PDIA6 pathway promotes NSCLC cell stemness via modulation of glycolytic metabolism (88). The gene discussed is SOX2; the disease is non-small cell lung carcinoma.